Waiting. During a health crisis, time is not always a friend.
“Waiting defines my cancer experience. It is inhumane to wait two weeks after cancer-removal surgery before I have treatment information. I’ve since heard from other patients who have had to wait even longer to hear the results or to schedule doctor appointments.”
Ultimately, I’m waiting, waiting, waiting …
The EU Cancer Information Portal will bring high quality, easy to understand, information for cancer patients and their families.
EU-CIP will also raise awareness of the EU Cancer Mission and Europe’s Beating
Cancer Plan.
They are building a home for reliable cancer information in the European Union.
Their goal is to facilitate access to general and personalised knowledge on cancer prevention, diagnosis, and treatment options.
They will create a common Library of Contents available to all EU Member States.
EU-CiP is for everyone! Cancer patients,Survivors,Families,Caregivers
and Healthcare staff.
https://www.europeancancer.org/resource/strategy-2024-2027.html
Throughout June, Emilia will share her whole story, from the first warning signs, diagnosis, through treatment, recovery, and life after cancer.Emilia will shine light on the patient pathway of endometrial cancer!
Emilia noticed she had some strange symptoms that wouldn’t go away.
It was scary, but she went to her doctor and explained her fear…..
Is this a fair Headline?
It is a step in the right direction to publish this data. The dashboard is here: https://app.powerbi.com/view?r=eyJrIjoiNTFmZjkyOWEtYWQyOS00ZTUzLWIzNjctM2M2MGVhNzIzZDgxIiwidCI6ImYwNTQ1MjZhLTZiY2MtNGE3OC05OTg0LWZhYTNmZjQ1NTViMCIsImMiOjl9
@mccarthymt7 I presume the dataset is complete and accurate. For some context, 15 years ago, in a public hospital clinic, for example, a consultant and 3 NCHDs would have an OPD of 60-80 people to see “scheduled” for a 3-4 hour clinic, that would routinely run for 6 hours. The consultant gave an opinion, and dictated a letter.
Today, many new consultants are in the clinic alone. They see all the patients, type their own letters, book the scans, request the molecular tests, arrange the follow up visits, and organise the interventions (e.g. chemotherapy appointments) by themselves. Being a consultant has become a different job.
Lynch Syndrome where we were and where we are now.
David Church is an Associate Professor, Cancer Research UK Advanced Clinician Scientist Fellow and group leader at the Centre for Human Genetics, University of Oxford, an Honorary Consultant Medical Oncologist at the Oxford Cancer Centre, and clinical lead for the NHSE Lynch Syndrome Transformation Project across the Central and South GMSA (population 10.5m).
His group’s research focuses on the identification and characterisation of novel biomarkers and therapeutic targets in endometrial and colorectal cancer, especially those relating to hyper/ultra-mutation and the anti-tumour immune response.
He leads the Genomics England 100K Genomes Project endometrial cancer domain and is a member of several clinical trial translational research groups including TransSCOT and TransPORTEC.
2025 LS UK Conference + 2024 event
Endometrial cancer risks, periods, pregnancy, HRT and menopause.
Objectives: There is limited evidence on health promotion interventions in people with hereditary cancer syndromes or on their main sources of support and information. This study aimed to understand these patients’ experiences and needs, including their information needs, their views on prevention and mental health, and the support they want from nurses. (small study)
Conclusions: People with hereditary cancer syndromes need professionals to be involved in their long-term management and to provide reliable information. As genomics are increasingly integrated in oncology, the need for professionals to support these populations will increase.
Implications for nursing practice: Nurses are crucial for promoting self-management and advocating for patient decision-making; however, they need skills and knowledge to do so. There is a need for nurses to get more involved in understanding hereditary cancer syndromes and an opportunity to take the lead in the care of these people.
The trial involved 1,879 people with Lynch syndrome who were given three different-sized doses of the painkiller.
The Cancer Prevention Project 3 study (CaPP3), supported by Cancer Research UK, involved patients taking a different daily dose of aspirin: 100mg, 300mg or 600mg. In the trial, a European-sized dose of 100 mg aspirin was used. The established dose is 75mg per day in the UK, and 81mg in the US.
People with Lynch syndrome have inherited a faulty gene which can increase their chances of developing some cancers – including bowel and womb cancer.
Prof John Burn, who led the international study, said he focused his research on those patients “because they get so many cancers”.
“We already have NICE guidance saying people with Lynch syndrome should be recommended to take aspirin. Now we should recommend a baby aspirin.” new results showed the lowest dose worked just as well as the larger doses.
“Roughly speaking, if someone with Lynch syndrome has about a 2% a year chance of getting mostly bowel cancers, we think if they take aspirin, that is halved – down to about 1% a year,” he explained.
In some people, aspirin can cause bleeding, so Prof Burn said he wanted health regulators to now recommend the lowest dose be given to Lynch syndrome patients.
Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this approach can be extended to all early-stage dMMR solid tumours, regardless of tumour site, is unknown.
A total of 117 patients were included in the analysis. Phase 2 study.
Among patients with early-stage dMMR solid tumours that were amenable to curative-intent surgery, neoadjuvant PD-1 blockade led to organ preservation in a high proportion of patients.
https://www.nejm.org/doi/full/10.1056/NEJMoa2404512?query=WB
Lynch Syndrome Ireland 